At a glance
- Originator Pfizer
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Mar 2000 No-Development-Reported for Cancer in USA (Unknown route)
- 10 Feb 1999 New profile
- 10 Feb 1999 Preclinical development for Cancer in USA (Unknown route)